Last reviewed · How we verify

NCT03954717

Pilot Study Evaluating Functional and Wellness Outcomes of the Shepherd CAN DO MS Program

Completed Last updated 2 August 2023
What this trial tests

trial testing Shepherd CAN DO Program in Multiple Sclerosis in 111 participants. Completed in 11 March 2022.

Timeline
14 May 2019
Primary endpoint
11 March 2022
11 March 2022

Quick facts

Lead sponsorShepherd Center, Atlanta GA
StatusCompleted
Study typeOBSERVATIONAL
Enrollment111
Start date14 May 2019
Primary completion11 March 2022
Estimated completion11 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Shepherd Center, Atlanta GA

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study evaluates the efficacy of the CAN DO Program for improving health, wellness, and quality of life in people with MS, and compares outcomes between people with MS who participate in the CAN DO Program to a control group of people with MS who do not participate in the CAN DO Program. The study also evaluates the impact of the CAN DO Program on support partners.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Shepherd Center, Atlanta GA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03954717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing